Teprotumumab for Thyroid Eye Disease-related Strabismus-Reference-Cited by-同舟云学术

Teprotumumab for Thyroid Eye Disease-related Strabismus

Published:2024-02-02 Issue: Volume: Page:
ISSN:0740-9303
Container-title:Ophthalmic Plastic & Reconstructive Surgery
language:en
Short-container-title:

Author:

Dallalzadeh Liane O.¹²^ORCID,Villatoro George A.¹,Chen Lillian³,Sim Myung S.³,Movaghar Mansoor⁴,Robbins Shira L.⁴,Karlin Justin N.⁵,Khitri Monica R.²,Velez Federico G.²,Korn Bobby S.¹⁶,Demer Joseph L.²⁷⁸,Rootman Daniel B.⁵,Granet David B.⁴,Kikkawa Don O.¹⁶

Affiliation:

1. Division of Oculofacial Plastic and Reconstructive Surgery, Department of Ophthalmology, University of California, San Diego, La Jolla, California, U.S.A.;

2. Pediatric Ophthalmology and Strabismus Division, Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California, U.S.A.

3. Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, U.S.A.

4. Division of Pediatric Ophthalmology and Adult Strabismus, Department of Ophthalmology, University of California, San Diego, La Jolla, California, U.S.A.

5. Orbital and Ophthalmic Plastic Surgery Division, Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California, U.S.A.

6. Division of Plastic Surgery, Department of Surgery, University of California, San Diego, La Jolla, California, U.S.A.

7. Department of Neurology, University of California, Los Angeles, Los Angeles, California, U.S.A.; and

8. Department of Bioengineering, University of California, Los Angeles, Los Angeles, California, U.S.A.

Abstract

Purpose: To assess and quantify teprotumumab’s effect on thyroid eye disease-related strabismus by change in measured horizontal and vertical deviations and change in extraocular motility. Methods: We reviewed a series of patients with thyroid eye disease-related strabismus treated with teprotumumab. Exclusion criteria included age under 18 years, strabismus of alternate etiology, or thyroid eye disease-related reconstructive surgery during the treatment course. Primary outcomes were absolute (prism diopters) and relative (%) differences in horizontal and vertical deviations in primary position at distance, as well as change in ductions of the more affected eye. Secondary outcomes included incidence and timing of strabismus surgery postteprotumumab. Results: Thirty-one patients were included, with mean age 63 years and thyroid eye disease duration 10 months. After teprotumumab, there was 6 prism diopters (39%) mean reduction in vertical deviation (p < 0.001), without significant change in mean horizontal deviation (p = 0.75). Supraduction, abduction, adduction, and infraduction significantly improved in the more restricted eye (p < 0.01, p < 0.01, p = 0.04, and p = 0.01, respectively). Thirty-five percent of patients underwent strabismus surgery posttreatment, at an average 10 months after last infusion. Conclusions: Teprotumumab produced a statistically significant reduction in vertical but not horizontal strabismus angles in primary position at distance. Extraocular motility in all 4 ductions also improved. A substantial minority of patients still required strabismus surgery following teprotumumab.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference30 articles.

1. Pathogenesis of Graves’ ophthalmopathy.;Bahn;N Engl J Med,1993

2. Thyroid eye disease: from pathogenesis to targeted therapies.;Yoon;Taiwan J Ophthalmol,2022

3. The pathophysiology of thyroid eye disease: implications for immunotherapy.;Douglas;Curr Opin Ophthalmol,2011

4. Pathogenesis of Graves ophthalmopathy: implications for prediction, prevention, and treatment.;Garrity;Am J Ophthalmol,2006

5. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.;Bartley;Trans Am Ophthalmol Soc,1994